Psoriasis. Plaque psoriasis
Conditions
Interventions
Intervention 1: The control group dissolve 10 gram of placebo(200 g=lactose and 100 g sugar )in a cup of warm water and when fasting they drink one third of cup every 15 minute.Meanwhile they will co
Placebo
Treatment - Drugs
The control group dissolve 10 gram of placebo(200 g=lactose and 100 g sugar )in a cup of warm water and when fasting they drink one third of cup every 15 minute.Meanwhile they will continue emollient
The intervention group dissolve 10 gram of whey protein in a cup of warm water and when fasting they drink one third of cup every 15 minute .Meanwhile they will continue emollient ointment that have u
Sponsors
Tehran University of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients above 18 years old ;skin involvement under 10 percent ;stable plaque psoriasis (which have been stable in extent and severity for at least 2 months) ; patients who haven’t been using psoralen for the past 28 days and UVB for the past 30 days ; patients who haven’t participated in any studies in the last month;patients who consent on participating in the study. The criteria that impede patients from entering the study : age under 18 and above 70 years old ;Patients suffering from other kinds of psoriasis like pustular, erythrodermic, or palmoplantar or psoriatic arthritis or patient having their face involved;skin involvement more than 10 percent ; past history of allergy to lactose ;patients suffering from the kidney stone disease; patients who use drugs that intensify psoriasis e.g.Beta blockers ?NSAIDs?Antimalarials ?Terbinafine?Ca channel blockers?Interleukins and Lithium ;Oral corticosteroids or immunosuppressants consumption during the 4 weeks prior to baseline ;pregnancy and lactation ;The patients suffering from uncontrolled cardiovascular and respiratory and hematological and urinary diseases ;those who have known cancer and cancer history in the last 5 years? those have metabolic diseases and water and electrical imbalance and infection; any record of allergy ; acute sensitivity and progressive form of disease and tendency to erythrodermy ;patients who must use systemic psoriasis drugs; patients are dissatisfaction with participating in the study . The criteria that lead to the exclusion of the patients who were participating in the study : skin events after taking the drug during the study ; infection on the lesion during the study ; patients getting pregnant during the study ; patient suffering from the kidney stone disease during the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity. Timepoint: At baseline -end of 8 and 12 weeks. Method of measurement: psoriasis activity and severity index.;Extent of the lesion. Timepoint: At baseline -end of 8 and 12 weeks. Method of measurement: BODY SURFACE AREA.;Quality of life. Timepoint: At baseline -end of 12 weeks. Method of measurement: persian valid version of Dermatology of life and quality index.;Intensity of pruritis. Timepoint: At baseline -end of 8 and 12 weeks. Method of measurement: VISUAL analog Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of Possibe gastrointestinal and skin complications. Timepoint: End of 8 and 12 weeks. Method of measurement: CTCAE) common terminology for Adverse Event v40.2009).;The photography of lesion. Timepoint: At baseline-end of 8 and 12 weeks. Method of measurement: The camera with 10 mega pixel sensor accuracy specifications .Canon EOS 400D Lens EFS18-55mm. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAkromosadat atyabi
School of Traditional Medicine ,Tehran University of Medical Science,Tehran,Iran
Outcome results
None listed